REYVOW OFFERS YOU THE FLEXIBILITY OF 3 DOSING OPTIONS1
REYVOW is available in 2 tablet strengths (50 mg, 100 mg) and 3 doses (50 mg, 100 mg, 200 mg):1
- Advise patients to swallow REYVOW tablets whole (do not split, crush, or chew them)1
- No more than 1 dose should be taken in 24 hours1
- A second dose of REYVOW has not been shown to be effective for the same migraine attack1
- REYVOW should not be taken unless the patient can wait at least 8 hours between dosing and driving or operating machinery1
- The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established1
SELECT IMPORTANT SAFETY INFORMATION
Driving Impairment
REYVOW may cause significant driving impairment. More sleepiness was reported at 8 hours following a single dose of REYVOW compared to placebo. Advise patients not to engage in potentially hazardous activities requiring complete mental alertness, such as driving a motor vehicle or operating machinery, for at least 8 hours after each dose of REYVOW. Patients who cannot follow this advice should not take REYVOW. Prescribers and patients should be aware that patients may not be able to assess their own driving competence and the degree of impairment caused by REYVOW.
Prescribing Guidance
How to prescribe REYVOW
Prescription Form Examples
- 50 mg tablets
SIG: PRN/1 DOSE PER 24 HOURS
DISPENSE: 8 TABLETS
REFILLS: ____ (Insert # of refills) - 100 mg tablets
SIG: PRN/1 DOSE PER 24 HOURS
DISPENSE: 8 TABLETS
REFILLS: ____ (Insert # of refills) - 200 mg (100 mg tablet x 2)
SIG: PRN/1 DOSE PER 24 HOURS
DISPENSE: 8 TABLETS
REFILLS: ____ (Insert # of refills)
Eligible patients can save on REYVOW
Governmental beneficiaries excluded; terms and conditions apply.
SEE THE OFFER
Reference:
- REYVOW [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.
INDICATION AND USAGE
REYVOW is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use: REYVOW is not indicated for the preventive treatment of migraine.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Driving Impairment
REYVOW may cause significant driving impairment. In a driving study, administration of single 50 mg, 100 mg, or 200 mg doses of REYVOW significantly impaired subjects' ability to drive. Additionally, more sleepiness was reported at 8 hours following a single dose of REYVOW compared to placebo. Advise patients not to engage in potentially hazardous activities requiring complete mental alertness, such as driving a motor vehicle or operating machinery, for at least 8 hours after each dose of REYVOW. Patients who cannot follow this advice should not take REYVOW. Prescribers and patients should be aware that patients may not be able to assess their own driving competence and the degree of impairment caused by REYVOW.
Central Nervous System Depression
REYVOW may cause central nervous system (CNS) depression, including dizziness and sedation. Because of the potential for REYVOW to cause sedation, other cognitive and/or neuropsychiatric adverse reactions, and driving impairment, REYVOW should be used with caution if used in combination with alcohol or other CNS depressants. Patients should be warned against driving and other activities requiring complete mental alertness for at least 8 hours after REYVOW is taken.
Serotonin Syndrome
In clinical trials, reactions consistent with serotonin syndrome were reported in patients treated with REYVOW who were not taking any other drugs associated with serotonin syndrome. Serotonin syndrome may also occur with REYVOW during coadministration with serotonergic drugs. Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular signs, and/or gastrointestinal signs and symptoms. The onset of symptoms usually occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. Discontinue REYVOW if serotonin syndrome is suspected.
Medication Overuse Headache
Overuse of acute migraine drugs may lead to exacerbation of headache. Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. Detoxification of patients including withdrawal of the overused drugs and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary.
ADVERSE REACTIONS
The most common adverse reactions associated with REYVOW (≥2% and greater than placebo in clinical studies) were dizziness, fatigue, paresthesia, sedation, nausea and/or vomiting, and muscle weakness.
ABUSE
REYVOW contains lasmiditan, a Schedule V controlled substance (C-V). REYVOW has abuse potential. Evaluate patients for risk of drug abuse and observe them for signs of lasmiditan misuse or abuse.
See Full Prescribing Information and Medication Guide.
LM HCP ISI 28SEP2020